NCT00002217已完成不适用
Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial
Glaxo Wellcome2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
详细描述
In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •CD4 count greater than 50 cells/mm
- •HIV RNA less than 50,000 copies/ml.
- •No active AIDS (excluding CD4 count less than 200 cells/mm3).
- •Ability to comply with dosing schedule and protocol evaluations.
- •Prior Medication:
- •AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
排除标准
- •Co-existing Condition:
- •Patients with any of the following symptoms or conditions are excluded:
- •Active AIDS (not excluding CD4 count less than 200).
- •Malabsorption syndrome affecting drug absorption.
- •Serious medical condition that would compromise safety of the patient.
- •Concurrent Medication:
- •AZT or NNRTIs.
- •More than 1 week treatment with any protease inhibitor.
- •Enrollment in any other investigational drug protocol.
- •Patients with the following prior conditions are excluded:
- •History of clinically relevant pancreatitis or hepatitis within the past 6 months.
- •Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Comparison of 141W94 and Indinavir in HIV-Infected PatientsHIV InfectionsNCT00002202Glaxo Wellcome460
已完成
2 期
A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV DrugsHIV InfectionsNCT00002364Glaxo Wellcome40
已完成
3 期
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed TreatmentHepatitis CNCT01585584University of Calgary11
已完成
3 期
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedHIV InfectionsNCT04542070ViiV Healthcare687
已完成
4 期
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIVHIV InfectionNCT00244712GlaxoSmithKline688